These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35787526)

  • 21. Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.
    Yao N; Huang S; Huang A; Song H
    Eur J Clin Pharmacol; 2022 Oct; 78(10):1667-1675. PubMed ID: 36006433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
    Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
    Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution pattern of UGT1A6 and UGT2B7 gene polymorphism and its impact on the pharmacokinetics of valproic acid and carbamazepine: Prospective genetic association study conducted in Pakistani patients with epilepsy.
    Saleh Faisal M; Jamil A; Ali N; Alshahrani AM; Almarshad F
    Gene; 2024 Jan; 892():147886. PubMed ID: 37820941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
    McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
    Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics of oxcarbazepine in the treatment of epilepsy.
    Yuan Y; Zhang S; Yuan Y; Yan X; Zhang L; Ran YW
    Pharmacogenomics; 2023 Apr; 24(6):335-343. PubMed ID: 37092337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers.
    Antunes NJ; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Marques MP; Lanchote VL
    J Pharm Biomed Anal; 2018 Feb; 149():442-447. PubMed ID: 29169112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.
    Chen X; Gu E; Wang S; Zheng X; Chen M; Wang L; Hu G; Cai JP; Zhou H
    J Chromatogr Sci; 2016 Mar; 54(3):334-42. PubMed ID: 26499119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
    Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
    Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Factors Impacting the Efficacy of Single or Combination Therapies of Valproic Acid, Carbamazepine, and Oxcarbazepine: A Longitudinal Observation Study.
    Peng Q; Ma M; Gu X; Hu Y; Zhou B
    Front Pharmacol; 2021; 12():641512. PubMed ID: 34017250
    [No Abstract]   [Full Text] [Related]  

  • 30. Development and Validation of a Highly Sensitive and Rapid LC-MS
    Ji Z; Li T; Zhao X; Ma W; Li Y; Huang J
    Molecules; 2022 Sep; 27(17):. PubMed ID: 36080439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy.
    Chen Y; Xu S; Wang Z; Zhao M; Wang H; Lu T; Zhao L
    Ther Drug Monit; 2018 Dec; 40(6):730-737. PubMed ID: 30169477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication.
    Vainionpää LK; Mikkonen K; Rättyä J; Knip M; Pakarinen AJ; Myllylä VV; Isojärvi JI
    Epilepsia; 2004 Mar; 45(3):197-203. PubMed ID: 15009219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.
    Shi L; Zhu M; Li H; Wen Z; Chen X; Luo J; Lin C; Zhang Z
    Eur J Clin Pharmacol; 2019 May; 75(5):655-663. PubMed ID: 30693367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
    Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
    Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous quantification of oxcarbazepine and its active metabolite in spiked human plasma using ultra performance liquid chromatography-MS/MS.
    Rajendran K; Chekraverthy BK; Devendran RS; Sajini RJ; Nagappan K
    Bioanalysis; 2021 Aug; 13(16):1259-1273. PubMed ID: 34463119
    [No Abstract]   [Full Text] [Related]  

  • 36. Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry.
    de Sousa Maia MB; do Nascimento DF; Martins IL; Cunha AN; de Lima FE; Bezerra FA; de Moraes MO; de Moraes ME
    J Pharm Biomed Anal; 2007 Oct; 45(2):304-11. PubMed ID: 17869472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
    Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
    Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen.
    Lin WW; Jiao Z; Wang CL; Wang HY; Ma CL; Huang PF; Guo XZ; Liu YW
    Ther Drug Monit; 2015 Feb; 37(1):76-83. PubMed ID: 24831653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
    Maschio M; Albani F; Jandolo B; Zarabla A; Contin M; Dinapoli L; Fabi A; Pace A; Baruzzi A
    J Neurooncol; 2008 Nov; 90(2):217-21. PubMed ID: 18612799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
    Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
    Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.